Alkermes plc
Long

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alf

ALKS: Alkermes plc
2021-10-25 07:00:00
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

Disclaimer